ANI Pharmaceuticals, Inc.

Valuation Analysis

About the Company

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANI Pharmaceuticals, Inc. Stock at a Glance

ANI Pharmaceuticals, Inc. (ANIP) is currently trading at $81.68 with a market capitalization of $1.9B. The trailing P/E ratio stands at 20.89x, with a forward P/E of 7.64x. The 52-week range spans from $62.14 to $99.50; the current price is 17.9% below the yearly high. Year-over-year revenue growth stands at +20.5%. The net profit margin stands at 9.98%.

💰 Dividend

ANI Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

7 analysts rate ANI Pharmaceuticals, Inc. (ANIP) on consensus: Strong Buy. The average price target is $112.71, implying +37.99% from the current price. Analyst price targets range from $100.00 to $124.00.

ANI Pharmaceuticals, Inc.: The Investment Case in Detail

ANI Pharmaceuticals, Inc. (ANIP) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 20.5% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 86.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 60.83%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

The Bear Case

Short interest sits at 17.84% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

What to Watch Next

• The forward P/E of 7.64x is meaningfully below the trailing 20.89x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 37.99% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (17.84%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy ANI Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.